|
|
|
|
|
Depakote: profile and news
Name That Episode! 06 Mar 2006 Restless legs or shaky legs: Conditions incongruent Mar 5, 2006 Migraine sufferers seek alternative to prescription relief Feb 22, 2006 Prescription drug Web site saves consumers money Feb 26, 2006 New York Prescription Drug Price Web Site Saves $17 Per ... Feb 28, 2006 Migraine sufferers share their misery in new documentary Mar 2, 2006 Man charged with DUI after car hits bike Mar 2, 2006 HealthWatch: Defeating Menstrual Migraine Attacks Feb 15, 2006 Holistic medicine offers hope to people suffering from migraine ... Feb 15, 2006 Linear Relationship of Valproate Serum Concentration to Response ... Feb 9, 2006 Olympic Hockey Goalie Triumphs Over Epilepsy Feb 9, 2006 Gunn conquers epilepsy to achieve Olympic dream Feb 17, 2006 Goalie Gunn's Edginess Can Be an Asset on the Ice Feb 14, 2006 Teammates’ journey goes beyond Turin Feb 17, 2006 ABBOTT LABORATORIES: Settlement reached on Depakote lawsuit Jan 25, 2006 Teva gets tentative FDA OK for Depakote Jan 12, 2006 Teva gets tentative FDA nod for generic Depakote Jan 12, 2006 Abbott Reports Record Sales, Earnings and Cash Flow in 2005 Jan 25, 2006 Abbott reaches deal with Andrx over epilepsy drug lawsuit Jan 24, 2006 Alternatives can cure migraines Jan 9, 2006 Happy Pills Don't Make Me Happy Jan 20, 2006 The Down Side of Popping Pills Jan 11, 2006 Man's rage on plane tied to mental illness Jan 24, 2006 9.5% of Americans battle depression Jan 25, 2006 The challenges of special education Jan 28, 2006 Medicare Woes Take High Toll on Mentally Ill Jan 21, 2006 Teva Announces Tentative Approval of Divalproex Sodium Delayed ... Jan 12, 2006 US court approves Wyeth-Teva settlement on Effexor Jan 15, 2006 Treatment Compliance in Patients With Co-Occurring Mental Illness ... Jan 23, 2006 Valproic acid, a common anti-seizure drug, could be effective for ... Jan 21, 2006 Excerpts From Night Falls Fast Jan 23, 2006 Young and fearless Jan 17, 2006 Depakote® ER Approved For Acute Manic Or Mixed Episodes ... 11 Dec 2005 FDA Approvals: Angiomax, Depakote ER, Hylenex Dec 8, 2005 FDA clears new use for Abbott's Depakote ER Dec 7, 2005 Abbott's Depakote(R) ER (Divalproex Sodium Extended-Release ... Dec 7, 2005 Abbott's Depakote ER (Divalproex Sodium Extended-Release Tablets) ... Dec 7, 2005 Valproic acid (Depakote) may help treat lupus Nov 20, 2005 FDA approves new indication for Abbott bi-polar drug Dec 9, 2005 Abbott's Depakote ER (Divalproex Sodium Extended-Release Tablets) ... Dec 7, 2005 Abbott's Depakote(R) ER (Divalproex Sodium Extended-Release ... Dec 7, 2005 Bipolar disorder not always what you think, doctor says Dec 8, 2005 Ailing child faces new hurdles Dec 5, 2005 Bhagia: Diagnosis key for bipolar patients Dec 9, 2005 Suits aim to block generic epilepsy drug Nov 22, 2005 With win over epilepsy, goalie aims for Turin berth Dec 4, 2005 (PRN) - ONStor Wins 'Product of the Year' From Enterprise Systems ... Dec 7, 2005 Cape Girardeau women plead guilty to child endangerment Dec 5, 2005 Olympics aren't goalie's only flame Dec 3, 2005 Saint Mary's joins search for Alzheimer's drug Nov 8, 2005 Rx drugs in cop's system are at issue in traffic death trial Sep 30, 2005 Ranbaxy gets tentative nod for anti-convulsion drug Sep 15, 2005 Mentally ill not using safety net Sep 25, 2005 Closings reflect trial strategies Oct 6, 2005 Few mentally ill have health care Sep 10, 2005 Teen Dies While Playing Soccer Sep 29, 2005 Six mental health drugs join Medicaid preferred-brands list Sep 12, 2005 Mental health drug list grows Sep 13, 2005 FDA panel rejects Abbott cancer pill Sep 14, 2005 Defendant's drinking record inadmissable at trial Oct 2, 2005 The Age of Autism: Case Number 88924 Sep 26, 2005 Slipping through the safety net? Oct 2, 2005 Navigating the safety net Oct 2, 2005 In Case You Missed "Montel" Oct 3, 2005 Family copes with mental illness nightmare Sep 29, 2005 Behavioral and Pharmacologic Treatment of Aggression in Children ... Oct 3, 2005 Troubled souls stick together on odyssey out of New Orleans Sep 18, 2005 Morgan Stanley sends Sensex to 8,146.65 Sep 13, 2005 16 men and their meds: an odd love story Sep 19, 2005 Group-home residents team up to escape disaster Sep 18, 2005 State briefs: Mood stabilizers added to safety net program Sep 10, 2005 Kaiser Daily Health Policy Report Highlights News Coverage of ... Sep 14, 2005 Fla. Medicaid, drug firm reach agreement on antipsychotic drug Sep 13, 2005 Disclosing Bipolar Disorder Sep 15, 2005 Intravenous Valproate Use in Bipolar II Disorder After Gastric ... Sep 24, 2005 Other information Indication For treatment and management of Seizure disorders; Mania and Prophylactic treatment of migraine headache Pharmacology Divalproex is an anticonvulsant and mood-stabilizing drug used primarily in the treatment of epilepsy and bipolar disorder. It is also used to treat migraine headaches and schizophrenia. In epileptics, Divalproex is used to control absence seizures, tonic-clonic seizures (grand mal), complex partial seizures, and the seizures associated with Lennox-Gastaut syndrome. Divalproex is believed to affect the function of the neurotransmitter GABA (as a GABA transaminase inhibitor) in the human brain. Divalproex dissociates to the valproate ion in the gastrointestinal tract. Mechanism Of Action Divalproex binds to and inhibits GABA transaminase. The drug's anticonvulsant activity may be related to increased brain concentrations of gamma-aminobutyric acid (GABA), an inhibitory neurotransmitter in the CNS, by inhibiting enzymes that catabolize GABA or block the reuptake of GABA into glia and nerve endings. Divalproex may also work by suppressing repetitive neuronal firing through inhibition of voltage-sensitive sodium channels. Drug Category Antimanic Agents; GABA Agents; Anticonvulsants; ATC:N03AG Brand Names/Synonyms Acetic Acid, Dipropyl-; Convulex; DPA; Depakene; Depakine; Depakote; Depakote Cp; Depakote Er; Depakote Sprinkle; Dipropylacetic Acid; Divalproex; Divalproex Sodium; Epilim; Epival; Ergenyl; Mylproin; N-Dipropylacetic Acid; N-Dpa; Propylvaleric Acid; SEMISODIUM VALPROATE; Valproate Semisodium; Valproic Acid; Valproic Acid Usp; Valproic Acid Usp24 Dosage Forms TABLET (ENTERIC-COATED) Absorption Not Available Interactions -->Interactions for Divalproex: Effects of Co-Administered Drugs on Valproate Clearance Drugs that affect the level of expression of hepatic enzymes, particularly those that elevate levels of glucuronosyltransferases, may increase the clearance of valproate. For example, phenytoin, carbamazepine, and phenobarbital (or primidone) can double the clearance of valproate. Thus, patients on monotherapy will generally have longer half-lives and higher concentrations than patients receiving poly-therapy with antiepilepsy drugs. In contrast,drugs that are inhibitors of cytochrome P450 isozymes, e.g., antidepressants, may be expected to have little effect on val-proate clearance because cytochrome P450 microsomal mediated oxidation is a relatively minor secondary metabolic pathway compared to glucuronidation and beta-oxidation. Because of these changes in valproate clearance, monitoring of valproate and concomitant drug concentrations should be increased whenever enzyme inducing drugs are introduced or withdrawn. The following list provides information about the potential for an influence of several commonly prescribed medications on valproate pharmacokinetics. The list is not exhaustive nor could it be, since new interactions are continuously being reported. Drugs for which a potentially important interaction has been observed Aspirin - A study involving the co-administration of aspirin at antipyretic doses (11 to 16 mg/kg) with valproate to pediatric patients (n=6) revealed a decrease in protein binding and an inhibition of metabolism of valproate. Valproate free fraction was increased 4-fold in the presence of aspirin compared to valproate alone. The ß-oxidation pathway consisting of 2-E-valproic acid, 3-OH-valproic acid, and 3-keto valproic acid was decreased from 25% of total metabolites excreted on valproate alone to 8.3% in the presence of aspirin. Caution should be observed if valproate and aspirin are to be co-administered. Felbamate - A study involving the co-administration of 1200 mg/day of felbamate with valproate to patients with epilepsy (n=10) revealed an increase in mean valproate peak concentration by 35% (from 86 to 115 µg/mL) compared to valproate alone. Increasing the felbamate dose to 2400 mg/day increased the mean valproate peak concentration to 133 µg/mL (another 16% increase). A decrease in valproate dosage may be necessary when felbamate therapy is initiated. Meropenem - Subtherapeutic valproic acid levels have been reported when meropenem was coadministered. Rifampin - A study involving the administration of a single dose of valproate (7 mg/kg) 36 hours after 5 nights of daily dosing with rifampin (600 mg) revealed a 40% increase in the oral clearance of valproate. Valproate dosage adjustment may be necessary when it is co-administered with rifampin. Drugs for which either no interaction or a likely clinically unimportant interaction has been observed Antacids - A study involving the co-administration of valproate 500 mg with commonly administered antacids (Maalox, Trisogel, and Titralac - 160 mEq doses) did not reveal any effect on the extent of absorption of valproate. Chlorpromazine - A study involving the administration of 100 to 300 mg/day of chlorpromazine to schizophrenic patients already receiving valproate (200 mg BID) revealed a 15% increase in trough plasma levels of valproate. Haloperidol - A study involving the administration of 6 to 10 mg/day of haloperidol to schizophrenic patients already receiving val-proate (200 mg BID) revealed no significant changes in valproate trough plasma levels. Cimetidine and Ranitidine - Cimetidine and ranitidine do not affect the clearance of valproate. Effects of Valproate on Other Drugs Valproate has been found to be a weak inhibitor of some P450 isozymes, epoxide hydrase, and glucuronosyltransferases. The following list provides information about the potential for an influence of valproate co-administration on the pharmacokinetics or pharmacodynamics of several commonly prescribed medications. The list is not exhaustive, since new interactions are continuously being reported. Drugs for which a potentially important valproate interaction has been observed Amitriptyline/Nortriptyline - Administration of a single oral 50 mg dose of amitriptyline to 15 normal volunteers (10 males and 5 females) who received valproate (500 mg BID) resulted in a 21% decrease in plasma clearance of amitriptyline and a 34% decrease in the net clearance of nortriptyline. Rare postmarketing reports of concurrent use of valproate and amitriptyline resulting in an increased amitriptyline level have been received. Concurrent use of valproate and amitriptyline has rarely been associated with toxicity. Monitoring of amitriptyline levels should be considered for patients taking valproate concomitantly with amitriptyline. Consideration should be given to lowering the dose of amitriptyline/nortriptyline in the presence of valproate. Carbamazepine/carbamazepine-10,11-Epoxide - Serum levels of carbamazepine (CBZ) decreased 17% while that of carbamazepine-10,11-epoxide (CBZ-E) increased by 45% upon co-administration of valproate and CBZ to epileptic patients. Clonazepam - The concomitant use of valproic acid and clonazepam may induce absence status in patients with a history of absence type seizures. Diazepam - Valproate displaces diazepam from its plasma albumin binding sites and inhibits its metabolism. Co-administration of valproate (1500 mg daily) increased the free fraction of diazepam (10 mg) by 90% in healthy volunteers (n=6). Plasma clearance and volume of distribution for free diazepam were reduced by 25% and 20%, respectively, in the presence of valproate. The elimination half-life of diazepam remained unchanged upon addition of valproate. Ethosuximide - Valproate inhibits the metabolism of ethosuximide. Administration of a single ethosuximide dose of 500 mg with valproate (800 to 1600 mg/day) to healthy volunteers (n=6) was accompanied by a 25% increase in elimination half-life of ethosux-imide and a 15% decrease in its total clearance as compared to ethosuximide alone. Patients receiving valproate and ethosuximide, espe-cially along with other anticonvulsants, should be monitored for alterations in serum concentrations of both drugs. Lamotrigine - In a steady-state study involving 10 healthy volunteers, the elimination half-life of lamotrigine increased from 26 to 70 hours with valproate co-administration (a 165% increase). The dose of lamotrigine should be reduced when co-administered with valproate. Serious skin reactions (such as Stevens-Johnson Syndrome and toxic epidermal necrolysis) have been reported with concomitant lamotrigine and valproate administration. See lamotrigine package insert for details on lamotrigine dosing with concomitant valproate administration. Phenobarbital - Valproate was found to inhibit the metabolism of phenobarbital. Co-administration of valproate (250 mg BID for 14 days) with phenobarbital to normal subjects (n=6) resulted in a 50% increase in half-life and a 30% decrease in plasma clearance of phenobarbital (60 mg single-dose). The fraction of phenobarbital dose excreted unchanged increased by 50% in presence of valproate. There is evidence for severe CNS depression, with or without significant elevations of barbiturate or valproate serum concentrations. All patients receiving concomitant barbiturate therapy should be closely monitored for neurological toxicity. Serum barbiturate concentrations should be obtained, if possible, and the barbiturate dosage decreased, if appropriate. Primidone, which is metabolized to a barbiturate, may be involved in a similar interaction with valproate. Phenytoin - Valproate displaces phenytoin from its plasma albumin binding sites and inhibits its hepatic metabolism. Co-administration of valproate (400 mg TID) with phenytoin (250 mg) in normal volunteers (n=7) was associated with a 60% increase in the free fraction of phenytoin. Total plasma clearance and apparent volume of distribution of phenytoin increased 30% in the presence of val-proate. Both the clearance and apparent volume of distribution of free phenytoin were reduced by 25%. In patients with epilepsy, there have been reports of breakthrough seizures occurring with the combination of valproate and phenytoin. The dosage of phenytoin should be adjusted as required by the clinical situation. Tolbutamide - From in vitro experiments, the unbound fraction of tolbutamide was increased from 20% to 50% when added to plasma samples taken from patients treated with valproate. The clinical relevance of this displacement is unknown. Warfarin - In an in vitro study, valproate increased the unbound fraction of warfarin by up to 32.6%. The therapeutic relevance of this is unknown; however, coagulation tests should be monitored if DEPAKOTE therapy is instituted in patients taking anticoagulants. Zidovudine - In six patients who were seropositive for HIV, the clearance of zidovudine (100 mg q8h) was decreased by 38% after administration of valproate (250 or 500 mg q8h); the half-life of zidovudine was unaffected. Drugs for which either no interaction or a likely clinically unimportant interaction has been observed: Acetaminophen - Valproate had no effect on any of the pharmacokinetic parameters of acetaminophen when it was concurrently administered to three epileptic patients. Clozapine - In psychotic patients (n=11), no interaction was observed when valproate was co-administered with clozapine. Lithium - Co-administration of valproate (500 mg BID) and lithium carbonate (300 mg TID) to normal male volunteers (n=16) had no effect on the steady-state kinetics of lithium. Lorazepam - Concomitant administration of valproate (500 mg BID) and lorazepam (1 mg BID) in normal male volunteers (n=9) was accompanied by a 17% decrease in the plasma clearance of lorazepam. Oral Contraceptive Steroids - Administration of a single-dose of ethinyloestradiol (50 µg)/levonorgestrel (250 µg) to 6 women on valproate (200 mg BID) therapy for 2 months did not reveal any pharmacokinetic interaction. |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |